Nektar Therapeutics
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
455 Mission Bay Blvd S, San Francisco, C...Phone Number
(415) 482-5300Website
www.nektar.comRevenue
$54.6 MillionStock Symbol
NKTRIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company focused on the research and development of innovative medicines designed to address serious unmet medical needs. The company is known for its expertise in advanced drug design and polymer conjugate technology, which it applies to enhance the effectiveness and safety of therapeutic compounds. Nektar Therapeutics concentrates on areas such as immunology, oncology, and autoimmune diseases, aiming to create treatments that modulate the immune system in precise and durable ways. Through a combination of in-house research and strategic collaborations, the company seeks to translate scientific insights into novel therapies that can improve patient outcomes.Explore more
Nektar Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nektar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Nektar Therapeutics launches new products
Earning: See what the market has to say on Nektar Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Nektar Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check out if Nektar Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Nektar Therapeutics
Check if Nektar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Nektar Therapeutics had a recent Job posting/layoffs
Nektar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Nektar Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Nektar Therapeutics
Compare insights from companies similar to Nektar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nektar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nektar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nektar Therapeutics.
Nektar Therapeutics financials insights
Gather financial insights about Nektar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$125M
2013
Corporate Investment
$25M
2014
Stock Offering
$117M
2015
Debt
$250M
2016
Corporate Investment
$20M
Stock Offering
$175.5M
2018
Share Placement
$850M
2024
Share Placement
$30M
Nektar Therapeutics Tech Stack
A closer look at the technologies used by Nektar Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Person-Based
Earnings, Finance
Project
will report 24-week off-treatment data from the REZOLVE-AA study in Q4 of this year, covering all 92 enrolled patients, with 52-week off-treatment data from the atopic dermatitis Phase IIb study expected in Q1 of next year, both intended to inform long-term maintenance dosing strategies for REZPEG.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
Nektar Therapeutics News & Media
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory...Nektar Therapeutics Announces Second Quarter 2026 Financial Results
SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable...Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Nektar...Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nektar Therapeutics
Sign Up For FreeTo access detailed company insights
Nektar Therapeutics is a biopharmaceutical company focused on the research and development of innovative medicines designed to address serious unmet medical needs. The company is known for its expertise in advanced drug design and polymer conjugate technology, which it applies to enhance the effectiveness and safety of therapeutic compounds. Nektar... Read More
